4D Molecular Therapeutics Inc
FDMT
Get informed when a big investor buys or sells
+ FollowMarket Cap$561.97M
Close$
$2.31
80.2% downside
Current Fair Value
80.2% downsideOvervalued by 80.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $561.97 Million |
|---|---|
| Enterprise Value | $511.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.42 |
| Beta | 2.69 |
| Outstanding Shares | 68,064,586 |
Return
| Return on Equity | -43.95% |
|---|---|
| Return on Assets | -36.37% |
| Return on Invested Capital | -44.26% |
Valuation & Multiples
| P/E Ratio | -4.04 |
|---|---|
| PEG | -12.09 |
| Price to Sales | 11.65 |
| Price to Book Ratio | 2.33 |
| Enterprise Value to Revenue | 5.75 |
| Enterprise Value to EBIT | -2.6 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-1.02
Average shareholder expectationRevenue Estimate
$3.62 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-1.02
Average shareholder expectationRevenue Estimate
$3.70 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 127.64% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.84%▼ 60.53% |
|---|---|
| Total Invested | $124.90M▼ 73.47% |
| Investors Holding | 50▼ 107.00% |
ESG Score
No data
About 4D Molecular Therapeutics Inc
83 employees4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power o...